乙型肝炎表面抗原清除后与疾病长期临床结局的关系
Relationship between Hepatitis B Surface Antigen Clearance and Long-Term Clinical Outcomes
DOI: 10.12677/ACM.2023.133592, PDF,  被引量   
作者: 胡小小, 石小枫*：重庆医科大学附属第二医院感染科，重庆
关键词: 慢性乙型肝炎；临床治愈；HBsAg清除；临床结局；Chronic Hepatitis B； Clinical Cure； HBsAg Clearance； Clinical Outcomes
摘要: 早在《2015慢性乙型肝炎防治指南》中已明确指出，慢性乙型肝炎的临床治愈已被作为理想的治疗终点。无论是表面抗原自发清除还是通过抗病毒治疗后实现的表面抗原清除，一部分慢乙肝患者已经实现了乙肝的临床治愈，但乙肝表面抗原清除并不是一劳永逸的，HBsAg清除的持久性及临床结局的改善相关研究有限，本文旨在就血清HBsAg清除后的长期临床结局行综述。
Abstract: As already stated in the 2015 Guidelines for the Prevention and Treatment of Chronic Hepatitis B, clinical cure of chronic hepatitis B has been regarded as the ideal therapeutic endpoint. Some pa-tients with chronic hepatitis B have achieved clinical cure of hepatitis B, whether it is spontaneous clearance of surface antigen or the clearance of surface antigen after antiviral treatment. However, hepatitis B surface antigen clearance is not permanent and relevant studies on the persistence of HBsAg clearance and improvement of clinical outcome are limited. This article aims to review the long-term clinical outcomes after serum HBsAg clearance.
文章引用：胡小小, 石小枫. 乙型肝炎表面抗原清除后与疾病长期临床结局的关系[J]. 临床医学进展, 2023, 13(3): 4123-4128. https://doi.org/10.12677/ACM.2023.133592

参考文献

[1] Zhao, H., Zhou, X. and Zhou, Y.H. (2020) Hepatitis B Vaccine Development and Implementation. Human Vaccines & Immunotherapeutics, 16, 1533-1544. [Google Scholar] [CrossRef] [PubMed]
[2] World Health Organi-zation Hepatitis B/Detail/Fact Sheets/News Room/Home. June 24 2022.
https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
[3] Lozano, R., Naghavi, M., Foreman, K., et al. (2012) Global and Regional Mortality from 235 Causes of Death for 20 Age Groups in 1990 and 2010: A Systematic Analysis for the Global Burden of Disease Study 2010. The Lancet, 380, 2095-2128. [Google Scholar] [CrossRef] 
[4] Yeo, Y.H., Tseng, T.C., Hosaka, T., et al. (2020) Incidence, Factors, and Patient-Level Data for Spontaneous HBsAg Seroclearance: A Cohort Study of 11,264 Patients. Clinical and Translational Gastroenterology, 11, e00196. [Google Scholar] [CrossRef] [PubMed]
[5] Taniguchi, H., Iwasaki, Y., Aimi, M., et al. (2020) Clinical Features of Chronic Hepatitis B Patients with Low Hepatitis B Surface Antigen Levels and Determinants of Hepatitis B Surface Antigen Seroclearance. JGH Open, 4, 698-706. [Google Scholar] [CrossRef] [PubMed]
[6] Zhu, L., Zhai, X., Wang, Q., et al. (2018) Incidence and Determinants of Spontaneous Hepatitis B Surface Antigen Seroclearance and Seroconversion in Hepatitis B e Antigen-Negative Chronic Infection Patients: A Population-Based Prospective Cohort. Journal of Viral Hepatitis, 25, 1588-1598. [Google Scholar] [CrossRef] [PubMed]
[7] Heathcote, E.J., Marcellin, P., Buti, M., et al. (2011) Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B. Gastroenterology, 140, 132-143. [Google Scholar] [CrossRef] [PubMed]
[8] Hsu, Y.C., Yeh, M.L., Wong, G.L.H., et al. (2021) Incidences and Determinants of Functional Cure during Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B. The Journal of Infectious Diseases, 224, 1890-1899. [Google Scholar] [CrossRef] [PubMed]
[9] Caviglia, G.P., Troshina, Y., Garro, E., et al. (2021) Usefulness of a Hepatitis B Surface Antigen-Based Model for the Prediction of Functional Cure in Patients with Chronic Hepatitis B Vi-rus Infection Treated with Nucleos (t) Ide Analogues: A Real-World Study. Journal of Clinical Medicine, 10, 3308. [Google Scholar] [CrossRef] [PubMed]
[10] Suzuki, F., Hosaka, T., Suzuki, Y., et al. (2019) Long-Term Outcome of Entecavir Treatment of Nucleos (t) Ide Analogue-Naïve Chronic Hepatitis B Patients in Japan. Journal of Gastroenterol-ogy, 54, 182-193. [Google Scholar] [CrossRef] [PubMed]
[11] Zhao, H., Kurbanov, F., Wan, M.B., et al. (2007) Genotype B and Younger Patient Age Associated with Better Response to Low-Dose Therapy: A Trial with Pegylated/Nonpegylated In-terferon-α-2b for Hepatitis Be Antigen—Positive Patients with Chronic Hepatitis B in China. Clinical Infectious Diseases, 44, 541-548. [Google Scholar] [CrossRef] [PubMed]
[12] Zhou, Y., Yan, R., Ru, G.Q., et al. (2019) Pegylated-Interferon Consolidation Treatment versus Nucleos (t) Ide Analogue Consolidation Treatment in Non-Cirrhotic Hepatitis B Patients with Hepatitis B e Antigen Seroconversion: An Open-Label Pilot trial. Hepatology International, 13, 422-430. [Google Scholar] [CrossRef] [PubMed]
[13] Sarin, S.K., Kumar, M., Lau, G.K., et al. (2016) Asian-Pacific Clinical Practice Guidelines on the Management of Hepatitis B: A 2015 Update. Hepatology International, 10, 1-98. [Google Scholar] [CrossRef] [PubMed]
[14] 宁琴, 陈良, 陈新月, 等. 慢性乙型肝炎临床治愈(功能性治愈)专家共识[J]. 中华临床感染病杂志, 2019, 12(4): 241-252.
[15] Ahn, S.H., Marcellin, P., Ma, X., et al. (2018) Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate plus Peginterferon alfa-2a: Week 120 Analysis. Digestive Diseases and Sciences, 63, 3487-3497. [Google Scholar] [CrossRef] [PubMed]
[16] Jun, D.W., Ahn, S.B., Kim, T.Y., et al. (2018) Efficacy of Pegylated Interferon Monotherapy versus Sequential Therapy of Entecavir and Pegylated Interferon in Hepatitis B e An-tigen-Positive Hepatitis B Patients: A Randomized, Multicenter, Phase IIIb Open-Label Study (POTENT Study). Chinese Medical Journal, 131, 1645-1651. [Google Scholar] [CrossRef] [PubMed]
[17] 喻一奇, 陈少隆, 张文宏. 核苷和核苷酸类药物联合聚乙二醇干扰素治疗慢性乙型肝炎的研究进展[J]. 临床肝胆病杂志, 2015, 31(9): 1513-1519.
[18] Yoshida, K., Enomoto, M., Tamori, A., et al. (2021) Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduc-tion in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-On Combination Therapy. International Journal of Molecular Sciences, 22, 1456. [Google Scholar] [CrossRef] [PubMed]
[19] Zhou, K., Contag, C., Whita-ker, E., et al. (2019) Spontaneous Loss of Surface Antigen among Adults Living with Chronic Hepatitis B Virus Infec-tion: A Systematic Review and Pooled Meta-Analyses. The Lancet Gastroenterology & Hepatology, 4, 227-238. [Google Scholar] [CrossRef] 
[20] Kim, G.A., Lim, Y.S., An, J., et al. (2014) HBsAg Sero-clearance after Nucleoside Analogue Therapy in Patients with Chronic Hepatitis B: Clinical Outcomes and Durability. Gut, 63, 1325-1332. [Google Scholar] [CrossRef] [PubMed]
[21] Marcellin, P., Gane, E., Buti, M., et al. (2013) Regression of Cir-rhosis during Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B: A 5-Year Open-Label Follow-Up Study. The Lancet, 381, 468-475. [Google Scholar] [CrossRef] 
[22] Kaur, S.P., Talat, A., Karimi-Sari, H., et al. (2022) Hepato-cellular Carcinoma in Hepatitis B Virus-Infected Patients and the Role of Hepatitis B Surface Antigen (HBsAg). Journal of Clinical Medicine, 11, 1126. [Google Scholar] [CrossRef] [PubMed]
[23] Kim, G.A., Lee, H.C., Kim, M.J., et al. (2015) Incidence of Hepatocel-lular Carcinoma after HBsAg Seroclearance in Chronic Hepatitis B Patients: A Need for Surveillance. Journal of Hepa-tology, 62, 1092-1099. [Google Scholar] [CrossRef] [PubMed]
[24] Alawad, A.S., Auh, S., Suarez, D., et al. (2020) Durability of Spontaneous and Treatment-Related Loss of Hepatitis B s Antigen. Clinical Gastroenterology and Hepatology, 18, 700-709.e3. [Google Scholar] [CrossRef] [PubMed]
[25] Yoo, S., Kim, J.Y., Lim, Y.S., et al. (2022) Impact of HBsAg Seroclearance on Late Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma after Surgical Resec-tion. Journal of Hepatology, 77, 939-946. [Google Scholar] [CrossRef] [PubMed]
[26] Choi, J., Yoo, S. and Lim, Y.S. (2021) Comparison of Long-Term Clinical Outcomes between Spontaneous and Therapy-Induced HBsAg Seroclearance. Hepatology, 73, 2155-2166. [Google Scholar] [CrossRef] [PubMed]
[27] Yip, T.C.F., Wong, V.W.S., Tse, Y.K., et al. (2021) Similarly Low Risk of Hepatocellular Carcinoma after either Spontaneous or Nucleos (t) Ide Analogue-Induced Hepatitis B Surface Antigen Loss. Alimentary Pharmacology & Therapeutics, 53, 321-331.

为你推荐